IP Library Granted Patent US 12,552,857
Granted Patent B2
US 12,552,857 · App. 17/604,964 · Granted Feb 17, 2026

Method for separation of antibodies or antibody fragments being devoid of an Fc region capable of binding to protein A

Inventors: Gustav Rodrigo (Uppsala, SE); Mats Ander (Uppsala, SE); Tomas Bjorkman (Uppsala, SE); Ronnie Palmgren (Uppsala, SE); Charlotte Brink (Uppsala, SE)
Assignee: Cytiva Bioprocess R&D AB
C07K16/1271C07K1/22C07K16/00C07K2317/55C07K2317/569C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,552,857
App. No.
17/604,964
Granted
Feb 17, 2026
Kind
B2
Abstract

The invention discloses a method for separation of antibodies or antibody fragments, comprising the steps of: a) providing a feed comprising antibodies or antibody fragments having a VH3 region and being devoid of an Fc region capable of binding to Protein A; b) contacting the feed with a separation resin having covalently coupled ligands, wherein the ligands comprise a polypeptide as defined by SEQ ID NO 1 and wherein the antibodies or antibody fragments bind to the separation resin; c) optionally washing the separation resin with a washing liquid; d) eluting the antibodies or antibody fragments from the separation resin with an elution liquid and recovering the antibodies or antibody fragments.

Claims (32)

1 . A method for separation of antibodies or antibody fragments, comprising the steps of:

a) providing a feed comprising antibodies or antibody fragments capable of binding to Protein A, where the antibodies or antibody fragments comprise a VH3 region and are devoid of an Fc region capable of binding to Protein A;

b) contacting said feed with a separation resin having ligands covalently coupled to a support, wherein said ligands consist essentially of a polypeptide as defined by SEQ ID NO 1:

AQX 1 AFYEILX 2 LPNLTEEQRX 3 AFIQSLKDDPSVSKAILAEAKKLNX 4

AQ

wherein:

X 1 =E, K, Y, T, F, L, W, I, M, V, A, H or R,

X 2 =H or K,

X 3 =N or A, and

X 4 =D, F, Y, W, K or R

and wherein said antibodies or antibody fragments bind to said separation resin;

c) optionally washing said separation resin with a washing liquid; and

d) eluting said antibodies or antibody fragments from said separation resin with an elution liquid and recovering said antibodies or antibody fragments.

2 . The method of claim 1 , wherein X 1 =E.

3 . The method of claim 1 , wherein X 2 =K.

4 . The method of claim 1 , wherein X 3 =N.

5 . The method of claim 1 , wherein X 4 =D.

6 . The method of claim 1 , wherein said ligands comprise multimers of said polypeptide, linked by linker regions comprising 0-15 amino acid residues.

7 . The method of claim 6 , wherein said multimers are tetramers, pentamers or hexamers.

8 . The method of claim 6 , wherein said multimers are coupled to said support via thioether links, derived from a C-terminal cysteine on said multimers.

9 . The method of claim 1 , wherein said support comprises crosslinked agarose beads.

10 . The method of claim 1 , wherein said support comprises crosslinked cellulose nanofibers.

11 . The method of claim 1 , wherein said feed is a clarified cell culture supernatant.

12 . The method of claim 1 , wherein said antibody fragments are selected from the group consisting of Fab, scFv, domain antibodies, nanobodies and BiTe.

13 . The method of claim 1 , wherein the binding strength of said antibody fragments to said separation resin is in the nanomolar range or stronger.

14 . The method of claim 1 , wherein said antibodies or antibody fragments are capable of binding to native Protein A via the VH3 region.

15 . The method of claim 1 , wherein the method comprises step c) and wherein contaminants and/or impurities are removed in step c).

16 . The method of claim 15 , wherein said washing liquid is a buffer of pH 5-7.

17 . The method of claim 1 , wherein said elution liquid is a buffer of pH 2-5.

18 . The method of claim 1 , further comprising, after step d), a step e) of cleaning said separation resin with a cleaning liquid of pH 13 or higher.

19 . The method of claim 18 , wherein said cleaning liquid comprises 0.5-2 M of an alkali metal hydroxide.

20 . The method of claim 18 , wherein steps a)-e) are repeated at least 50 times.

Assignments (2)
CHANGE OF NAME Recorded Jan 20, 2022
From: GE HEALTHCARE BIOPROCESS R & D AB
To: CYTIVA BIOPROCESS R & D AB
Reel/Frame 058787/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2021
From: RODRIGO, GUSTAV; ANDER, MATS; BJORKMAN, TOMAS; PALMGREN, RONNIE; BRINK, CHARLOTTE
To: GE HEALTHCARE BIOPROCESS R & D AB
Reel/Frame 057874/0400 →
Continuity (2)
Provisional Application 62839840 · Apr 29, 2019
Related Publication 20220315647A1 · Oct 6, 2022
References Cited (32)
US 20210087227A1 · Rodrigo et al. · 2021 [cited by applicant]
CN 112940090A · 2021 [cited by applicant]
EP 2412809A1 · 2012 [cited by applicant]
EP 3521304A1 · 2019 [cited by applicant]
EP 3757123A1 · 2020 [cited by applicant]
JP 2017095503A · 2017 [cited by applicant]
WO 0063243A · 2000 [cited by applicant]
WO 2007097361A1 · 2007 [cited by applicant]
WO 2009019117A1 · 2009 [cited by applicant]
WO 2009146755A1 · 2009 [cited by applicant]
WO 2010110288A1 · 2010 [cited by applicant]
WO WO2017194594 · 2017 [cited by examiner]
WO WO2017194596A1 · 2017 [cited by applicant]
WO 2017022759A1 · 2018 [cited by applicant]
WO WO2018215503A1 · 2018 [cited by applicant]
WO 2020068511A1 · 2020 [cited by applicant]
WO 2023046886A1 · 2023 [cited by applicant]
Bouvet et al. ‘Immunoglobulin Fab fragment-binding proteins.’ International Journal of Immunopharmacology: 16(5-6):419-424, 1994. [cited by examiner]
Graille M. et al. “Crystal Structure of a [cited by applicant]
Gerald Platteau et al. “Purification of antibody fragments and single domain antibodies with Amsphere (TM) A3 Protein A resin,” Oct. 5, 2017, pp. 1-12, retrieved from Internet: URL:https://pdfs.semanticscholar.org/cf0e/… [cited by applicant]
PCT International Search Report and Written Opinion for PCT/EP2020/061826 mailed Aug. 28, 2020 (14 pages). [cited by applicant]
International Search Report and Written Opinion of PCT/EP2023/056401, mailed Jul. 17, 2023 (20 pages). [cited by applicant]
Michael D. Mclean, et al. “Purification of the therapeutic antibody trastuzumab from genetically modified plants using safflower Protein A-oleosin oilbody technology”, Transgenic Research, Kluwer Academic Publishers—Ple… [cited by applicant]
Susanne Gülich, et al. “Protein engineering of an IgG-binding domain allows milder elution conditions during affinity chromatography”, Journal of Biotechnology, Elsevier, Amsterdam NL, vol. 76, Jan. 1, 2000 (Jan. 1, 200… [cited by applicant]
Therese A. Seldon, et al. “Improved Protein-A separation of VH3 Fab from FC after Papain Digestion of Antibodies” Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, JP, vol. 34, No. 12, Dec. 1, 1986 … [cited by applicant]
Martin Linhult, et al. “Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach”, Proteins: Structure, Function, and Bioinformatics, John Wiley & Sons, Inc, US,… [cited by applicant]
Heikkinen, et al., “NMR Structure Determinations of Small Proteins Using Only One Fractionally 20% 13C− and Uniformly 100% 15N-Labeled Sample,” Molecules, 26, 747, 2021. [cited by applicant]
Search Report Issued in GB Patent Application No. GB2203478.9, mailed Sep. 15, 2022. (5 pages). [cited by applicant]
First Office Action in corresponding JP Application No. 2021-564361, mailed Jun. 3, 2024 (8 pages). [cited by applicant]
Dai, Journal of Chromatography A, 2016, vol. 1463, pp. 81-89. [cited by applicant]
Bach, Journal of Chromatography A, 2015, vol. 1409, pp. 60-69. [cited by applicant]
Wang, International Journal of Clinical Experimental Medicine, 2017, vol. 10, No. 10, pp. 14244-14255. [cited by applicant]